Yae Jean Kim

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia
    Yae Jean Kim
    Laboratory of Malaria and Vector Research, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Trop Med Hyg 73:125-30. 2005
  2. ncbi Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:2939-41. 2004
  3. ncbi Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome
    Jamie Robyn
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Br J Haematol 132:286-92. 2006
  4. ncbi Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome
    Yae Jean Kim
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Hematol 82:615-24. 2007
  5. ncbi Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700
    Yae-Jean Kim
    NIAID, NIH, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 114:1449-55. 2004

Detail Information

Publications5

  1. ncbi Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia
    Yae Jean Kim
    Laboratory of Malaria and Vector Research, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Trop Med Hyg 73:125-30. 2005
    ..Although the EDN and ECP polymorphisms appear unlikely to be associated with the development of TPE, further analyses will be more definitive...
  2. ncbi Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:2939-41. 2004
    ..These data suggest that anti-IL-5 therapy may be useful in the treatment of HES irrespective of the underlying etiology, although the observed rebound eosinophilia and attenuation of response require further study...
  3. ncbi Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome
    Jamie Robyn
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Br J Haematol 132:286-92. 2006
    ..These results suggest that the mutation arises in a pluripotential haematopoietic progenitor cell capable of giving rise to multiple lineages. The basis for the preferential expansion of eosinophils and mast cells remains unclear...
  4. ncbi Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome
    Yae Jean Kim
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Hematol 82:615-24. 2007
    ..Eosinophilia defines a distinct subgroup of ALPS patients with increased serum IgE levels, increased numbers of PBL of multiple lineages, and higher mortality from infectious complications...
  5. ncbi Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700
    Yae-Jean Kim
    NIAID, NIH, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 114:1449-55. 2004
    ..CONCLUSIONS: The rebound eosinophilia after SCH55700 treatment is a result of a serum factor that enhances eosinophil survival. Reversal of this effect by the addition of antibody to IL-5 suggests that this factor may be IL-5 itself...